Doxorubicin, Cisplatin, High-dose Methotrexate, and Ifosfamide for Osteosarcoma

2007 ◽  
Vol 42 (9) ◽  
pp. 801-811 ◽  
Author(s):  
John E. Mbue ◽  
Dominic A. Solimando ◽  
J. Aubrey Waddell
Keyword(s):  
Cancer Chemotherapy ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Malignant Diseases ◽  
Dose Methotrexate ◽  
Toxic Agents

The increasing complexity of cancer chemotherapy now requires that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant diseases.

Cancer Chemotherapy Update - Cisplatin, Doxorubicin, and High-dose Methotrexate for Osteosarcoma

2007 ◽  
Vol 42 (8) ◽  
pp. 702-710
Author(s):  
Carmen Debellas ◽  
Dominic A. Solimando ◽  
J. Aubrey Waddell
Keyword(s):  
Cancer Chemotherapy ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Malignant Diseases ◽  
Dose Methotrexate ◽  
Toxic Agents

The increasing complexity of cancer chemotherapy increases the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant diseases.

High-Dose Cytarabine (HIDAC) plus Daunorubicin for Remission Induction of Acute Myelogenous Leukemia

2003 ◽  
Vol 38 (1) ◽  
pp. 20-24
Author(s):  
J. Aubrey Waddell ◽  
Paula Doulaveris ◽  
Dominic A. Solimando
Keyword(s):  
Cancer Chemotherapy ◽  
Acute Myelogenous Leukemia ◽  
Myelogenous Leukemia ◽  
Remission Induction ◽  
High Dose ◽  
Malignant Diseases ◽  
Toxic Agents ◽  
High Dose Cytarabine ◽  
Acute Myelogenous ◽  
Investigational Agents

The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases, reviewing issues related to the preparation, dispensing, and administration of cancer chemotherapy.

Decision-making in high-dose methotrexate cancer chemotherapy

1977 ◽  
Vol 2 (3) ◽  
pp. 163-172 ◽  
Author(s):  
T. L. Lincoln ◽  
J. Aroesty ◽  
G. F. Groner ◽  
K. L. Willis ◽  
P. F. Morrison ◽  
...  
Keyword(s):  
Decision Making ◽  
Cancer Chemotherapy ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Dose Methotrexate

High-Dose Cytarabine for Consolidation and Relapse Therapy in Acute Myelogenous Leukemia

2003 ◽  
Vol 38 (2) ◽  
pp. 118-178
Author(s):  
Paula Doulaveris ◽  
Dominic A. Solimando ◽  
J. Aubrey Waddell
Keyword(s):  
Cancer Chemotherapy ◽  
Acute Myelogenous Leukemia ◽  
Myelogenous Leukemia ◽  
High Dose ◽  
Malignant Diseases ◽  
Toxic Agents ◽  
High Dose Cytarabine ◽  
Acute Myelogenous ◽  
Investigational Agents ◽  
Relapse Therapy

The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases, reviewing issues related to the preparation, dispensing, and administration of cancer chemotherapy.

High-dose methotrexate-induced reversible grade 4 hyperbilirubinaemia and transaminitis in an adolescent with Burkitt Leukaemia

2021 ◽  
Vol 14 (1) ◽  
pp. e237512
Author(s):  
Sanjeev Khera ◽  
Randhir Ranjan ◽  
Sateesh Ramachandran ◽  
Ajay Beriwal
Keyword(s):  
Liver Injury ◽  
Clinical Significance ◽  
Short Latency ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Drug Induced ◽  
Common Cause ◽  
Drug Induced Liver Injury ◽  
Dose Methotrexate

Symptomatic drug-induced liver injury (DILI) is an uncommon problem. Direct DILI is dose-related, predictable with short latency (hour to days) and is generally associated with transient and reversible transaminitis without jaundice. Antimetabolites including methotrexate are a common cause for direct DILI. Hepatotoxicity associated with high-dose methotrexate (HD-MTX) is generally transient and includes reversible elevation of transaminase in up to 60% and associated hyperbilirubinaemia (≤grade 2) in 25% of courses and therefore is of no clinical significance. Severe grades of DILI with HD-MTX (grade ≥4) are extremely rare. We describe an adolescent with Burkitt leukaemia who had reversible grade 4 DILI including hyperbilirubinaemia postfirst course of HD-MTX. Rechallenge with two-third dose of HD-MTX in subsequent chemotherapeutic cycle did not cause recurrence of DILI.

Sign in / Sign up

Export Citation Format

Share Document